- Home
- NBBK vs JANX Comparison
NBBK vs JANX Comparison
Compare NBBK & JANX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NBBK | JANX |
|---|---|---|
| Founded | 1892 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 926.5M | 840.4M |
| IPO Year | 2023 | 2021 |
Fundamental Metrics
Financial Performance| Metric | NBBK | JANX |
|---|---|---|
| Price | $20.88 | $16.20 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 2 | 13 |
| Target Price | $23.50 | ★ $47.00 |
| AVG Volume (30 Days) | 244.0K | ★ 1.4M |
| Earning Date | 04-22-2026 | 05-08-2026 |
| Dividend Yield | ★ 1.43% | N/A |
| EPS Growth | ★ 25.23 | N/A |
| EPS | ★ 0.36 | N/A |
| Revenue | N/A | ★ $10,000,000.00 |
| Revenue This Year | $45.15 | N/A |
| Revenue Next Year | $4.18 | N/A |
| P/E Ratio | $58.42 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $16.76 | $12.12 |
| 52 Week High | $22.86 | $35.34 |
Technical Indicators
Market Signals| Indicator | NBBK | JANX |
|---|---|---|
| Relative Strength Index (RSI) | 54.54 | 67.35 |
| Support Level | $20.11 | $13.00 |
| Resistance Level | $22.71 | $16.60 |
| Average True Range (ATR) | 0.49 | 0.70 |
| MACD | 0.03 | 0.18 |
| Stochastic Oscillator | 50.25 | 97.71 |
Price Performance
Historical ComparisonAbout NBBK NB Bancorp Inc.
NB Bancorp Inc operates as the holding company of Needham Bank. The group's business consists of taking deposits from the general public and investing those deposits, together with funds generated from operations, in commercial real estate and multifamily loans, one- to four-family residential real estate loans, construction and land development loans, commercial and industrial loans, consumer loans, and other related services.
About JANX Janux Therapeutics Inc.
Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. The proprietary technology of the company has enabled the development of distinct bispecific platforms: Tumor Activated T Cell Engagers (TRACTr), Tumor Activated Immunomodulators (TRACIr), and Adaptive Immune Response Modulator (ARM) platforms. The TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain, while the TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain.